v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenues:        
Revenue from collaborative arrangement $ 0 $ 0 $ 0 $ 65,343
Operating expenses:        
Research and development 10,826,549 14,521,407 24,896,656 30,612,309
General and administrative 7,797,973 8,563,112 15,677,859 17,588,082
Total operating expenses 18,624,522 23,084,519 40,574,515 48,200,391
Loss from operations (18,624,522) (23,084,519) (40,574,515) (48,135,048)
Other income (expense):        
Interest income 363,847 610,638 803,440 1,418,715
Change in fair value of common stock warrant liabilities 13,868,616 (1,878,010) 18,006,319 1,834,862
Gain (loss) on investment in affiliated entity 0 776,373 (2,103,688) 1,471,504
Net unrealized gain on available-for-sale equity securities 94,221 759,289 173,298 899,523
Other expense, net (1,714,620) (703,183) (2,000,110) (703,665)
Net loss $ (6,012,458) $ (23,519,412) $ (25,695,256) $ (43,214,109)
Net loss per share        
Basic (in dollars per share) $ (0.07) $ (0.61) $ (0.34) $ (1.12)
Diluted (in dollars per share) $ (0.07) $ (0.61) $ (0.34) $ (1.12)
Weighted average number of common shares used to compute net loss per share        
Basic (in shares) 81,619,113 38,830,053 75,395,090 38,722,451
Diluted (in shares) 81,619,113 38,830,053 75,395,090 38,722,451